Every few years, a type 1 diabetes study comes along that makes the entire diabetes community stop and pay attention.
Right now, that study is happening at the University of Chicago Medicine.
Twelve people with longstanding type 1 diabetes have become insulin-independent after receiving transplanted islet cells and a novel immune therapy called tegoprubart.
Let me say that again: Twelve people who previously relied on insulin daily are now producing enough of their own insulin to maintain healthy blood sugar levels without injections or an insulin pump.
That’s not a small result. That’s huge.
But before we start throwing around words like “cure,” it’s important to understand what these results actually mean—and why researchers are paying such close attention.
The Real Breakthrough May Not Be the Cells
Most headlines focus on the fact that participants received transplanted islet cells. And yes, that’s important. But the more interesting story may actually be what happened after those cells were transplanted.
Historically, one of the biggest challenges in islet cell transplantation has been keeping those cells alive and functioning long-term. The immune system tends to recognize transplanted cells as foreign and attack them.
That’s where tegoprubart comes in.
The drug is designed to help prevent that immune attack, allowing transplanted insulin-producing cells to survive and continue making insulin. And based on the results so far, it appears to be working remarkably well. Researchers aren’t just seeing improved blood sugar levels.
They’re seeing complete insulin independence. That’s why so many scientists are excited.
Why This Doesn’t Solve Type 1 Diabetes Yet
As impressive as these results are, there are still major obstacles standing between this study and a therapy that could be offered broadly to people living with type 1 diabetes.
The first challenge is the source of the cells. The islet cells used in this study came from deceased organ donors. Unfortunately, there simply aren’t enough donor pancreases available to treat the millions of people living with type 1 diabetes. Researchers have always known this.
The donor cells are helping answer an important scientific question, but they aren’t a scalable solution. The long-term goal is to combine successful immune protection with manufactured insulin-producing cells that can be produced in large quantities.
That’s where much of the field is headed right now.
The Treatment Is Still Intensive
Another important reality check is that this treatment isn’t simple. Participants receive tegoprubart through an IV infusion every 21 days. For many people, that’s a significant commitment. Even if the treatment continues to prove effective, researchers will eventually need to make it easier and more practical for everyday use.
Most people aren’t going to want lifelong infusion appointments every three weeks. That doesn’t mean the therapy won’t succeed. It simply means there is still room for improvement.
Tegoprubart Isn’t Working Alone
There’s another detail worth mentioning. Participants aren’t receiving only tegoprubart. The treatment regimen also includes corticosteroids and Myfortic, both of which affect immune activity.
That means researchers are still learning exactly how these therapies work together. Science is rarely as straightforward as a headline makes it seem. What we know today is that the overall treatment approach is producing extraordinary results.
What we don’t know yet is precisely how much each individual component contributes to those outcomes.
This Study Is Opening Doors
One thing that’s often misunderstood is the role of this study itself. This isn’t a large FDA registration trial designed to gain immediate approval.
It’s an investigator-led study conducted by Dr. Piotr Witkowski and his team at the University of Chicago.
Its purpose is to answer critical scientific questions. And so far, the answers have been extremely encouraging.
The results have been so strong that Eledon is now working with the FDA to better understand what a future regulatory pathway could look like for tegoprubart in islet cell transplantation. The company is also supporting an additional investigator-led study involving islet transplant recipients who have impaired kidney function.
In other words, these findings aren’t ending the conversation. They’re expanding it.
Why This Matters Beyond Eledon
Perhaps the most exciting thing about these results is that their impact may extend far beyond a single company or a single study.
If tegoprubart truly proves capable of protecting transplanted insulin-producing cells, it could potentially become part of future cell replacement therapies developed by many different organizations.
The type 1 diabetes research community has spent years searching for two pieces of the puzzle: A reliable source of insulin-producing cells.
And a reliable way to protect those cells from immune attack. This study suggests researchers may be making meaningful progress on the second piece. And that’s a very big deal.
A Reason for Optimism
People living with type 1 diabetes have heard promises of cures for decades. That history makes many of us cautious whenever exciting results emerge. And honestly, that’s fair. Healthy skepticism is part of living with a condition that has generated countless headlines over the years.
But it’s also okay to recognize when something truly stands out.
Twelve people with longstanding type 1 diabetes have achieved insulin independence. That’s real. It’s measurable. And it’s something researchers are taking very seriously.
Will this exact treatment become the cure for type 1 diabetes? Probably not. Will the lessons learned from this study help shape the future of cell replacement therapies? Very possibly.
And for now, that’s what makes these results worth watching.
Ginger Vieira has lived with type 1 diabetes since 1999 along with a few other chronic illnesses! She is the Cofounder of the Diabetes Nerd Network and the Diabetes Nerd Marketing agency. Ginger has authored hundreds of articles and several books, including Exercise with Type 1 Diabetes, Pregnancy with Type 1 Diabetes, Dealing with Diabetes Burnout, and Stop Overeating During Lows. Over her 20-year career (so far) in diabetes, she’s produced hundreds of articles and videos about life with diabetes. Her background includes a Bachelor of Science in professional writing and certifications in coaching, personal training, powerlifting, and Ashtanga yoga. Find Ginger’s YOUTUBE, PODCAST, INSTAGRAM, and LINKEDIN.